- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (FDA & EMA (2016))|
|International Nonproprietary Names|
|LY-2439821 | LY2439821 | Taltz®|
|Ixekizumab binds to IL-17A and blocks its action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A protein BLAST search using the variable region of the heavy chain of ixekizumab identifies this as sequence 118 from patent US7838638 . In this patent binding affinity data for human IL-17 is provided for several antibody clones, but it does not specify which was chosen as ixekizumab, although mAbs 126, 121 and 104 did undergo additional experimental investigations.
|GtoPdb PubChem SID||187051842|
|Search PubMed clinical trials||ixekizumab|
|Search PubMed titles||ixekizumab|
|Search PubMed titles/abstracts||ixekizumab|